LSA
RLMD icon

Leonteq Securities AG’s Relmada Therapeutics RLMD Stock Holding History

Leonteq Securities AG’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,000
Closed -$24K – 1273
2023
Q3 		$24K Hold
8,000
– – ﹤0.01% 928
2023
Q2 		$19.7K Hold
8,000
– – ﹤0.01% 965
2023
Q1 		$18.1K Hold
8,000
– – ﹤0.01% 936
2022
Q4 		$27.9K Buy
+8,000
New +$70.3K ﹤0.01% 929

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Leonteq Securities AG's RLMD Position: Q4 2023 in Review

Leonteq Securities AG sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 8,000 shares — an estimated $24K sold.

Leonteq Securities AG first reported a position in RLMD in Q4 2022 and held it in 4 quarters. The position peaked at $27.9K in Q4 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Leonteq Securities AG reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Leonteq Securities AG sold 8,000 Relmada Therapeutics shares in Q4 2023, an estimated $24K.
  • Leonteq Securities AG first reported a position in Relmada Therapeutics in Q4 2022 and held it in 4 quarters.
  • Leonteq Securities AG's Relmada Therapeutics position peaked at $27.9K in Q4 2022.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Leonteq Securities AG's 13F filing for Q4 2023, filed 11 Mar 2026.